BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26243483)

  • 1. Preprocedural Albumin Levels and Risk of In-Stent Restenosis After Coronary Stenting With Bare-Metal Stent.
    Celik IE; Yarlioglues M; Kurtul A; Duran M; Koseoglu C; Oksuz F; Aksoy O; Murat SN
    Angiology; 2016 May; 67(5):478-83. PubMed ID: 26243483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preprocedural red blood cell distribution width predicts bare metal stent restenosis.
    Yildiz A; Tekiner F; Karakurt A; Sirin G; Duman D
    Coron Artery Dis; 2014 Sep; 25(6):469-73. PubMed ID: 24614629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute coronary syndrome - a frequent clinical manifestation of bare metal in-stent restenosis.
    Drozd J; Wójcik J; Małek R; Korona B; Zapolski T; Wysokiński A
    Kardiol Pol; 2010 Jun; 68(6):637-45. PubMed ID: 20806192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting.
    Zhao K; Li YJ; Gao S
    Coron Artery Dis; 2015 May; 26(3):220-4. PubMed ID: 25647458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations.
    Magalhaes MA; Minha S; Chen F; Torguson R; Omar AF; Loh JP; Escarcega RO; Lipinski MJ; Baker NC; Kitabata H; Ota H; Suddath WO; Satler LF; Pichard AD; Waksman R
    Circ Cardiovasc Interv; 2014 Dec; 7(6):768-76. PubMed ID: 25466551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of the CHA2DS2-VASc Score in Predicting In-Stent Restenosis Among Patients Undergoing Revascularization With Bare-Metal Stents.
    Kurtul A
    Clin Appl Thromb Hemost; 2018 May; 24(4):589-595. PubMed ID: 28675046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
    Almalla M; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Relationship Between Lymphocyte-to-Monocyte Ratio and Bare-Metal Stent In-Stent Restenosis in Patients With Stable Coronary Artery Disease.
    Murat SN; Yarlioglues M; Celik IE; Kurtul A; Duran M; Kilic A; Oksuz F
    Clin Appl Thromb Hemost; 2017 Apr; 23(3):235-240. PubMed ID: 26759373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis.
    Pleva L; Kukla P; Zapletalova J; Hlinomaz O
    BMC Cardiovasc Disord; 2017 Jun; 17(1):168. PubMed ID: 28651572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between drug-coated balloon angioplasty and second-generation drug-eluting stent placement for the treatment of in-stent restenosis after drug-eluting stent implantation.
    Kang IS; Shehata I; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Heart Vessels; 2016 Sep; 31(9):1405-11. PubMed ID: 26337620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of the platelet-to-lymphocyte ratio in predicting bare-metal stent restenosis.
    Yılmaz S; Sen F; Ünal S; Yayla C; Özeke Ö; Aras D; Topaloglu S; Aydogdu S
    Scand Cardiovasc J; 2015 Feb; 49(1):39-44. PubMed ID: 25414124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
    Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García Del Blanco B; Seidelberger B; Iñiguez A; Gómez-Recio M; Masotti M; Velázquez MT; Sanchís J; García-Touchard A; Zueco J; Bethencourt A; Melgares R; Cequier A; Dominguez A; Mainar V; López-Mínguez JR; Moreu J; Martí V; Moreno R; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
    J Am Coll Cardiol; 2014 Apr; 63(14):1378-86. PubMed ID: 24412457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis.
    Habara S; Iwabuchi M; Inoue N; Nakamura S; Asano R; Nanto S; Hayashi Y; Shiode N; Saito S; Ikari Y; Kimura T; Hosokawa J; Nakamura M; Kotani J; Kozuma K; Mitsudo K
    Am Heart J; 2013 Sep; 166(3):527-33. PubMed ID: 24016503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous coronary intervention triggers a systemic inflammatory response in patients treated for in-stent restenosis -- comparison with stable and unstable angina.
    Kozinski M; Krzewina-Kowalska A; Kubica J; Zbikowska-Gotz M; Dymek G; Piasecki R; Sukiennik A; Grzesk G; Bogdan M; Chojnicki M; Dziedziczko A; Sypniewska G
    Inflamm Res; 2005 May; 54(5):187-93. PubMed ID: 15953990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Drug-Eluting Balloons for Patients With In-Stent Restenosis: A Meta-Analysis of 8 Randomized Controlled Trials.
    Gao S; Shen J; Mukku VK; Wang MJ; Akhtar M; Liu W
    Angiology; 2016 Aug; 67(7):612-21. PubMed ID: 26483569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluation.
    Zbinden R; von Felten S; Wein B; Tueller D; Kurz DJ; Reho I; Galatius S; Alber H; Conen D; Pfisterer M; Kaiser C; Eberli FR
    Cardiovasc Ther; 2017 Feb; 35(1):19-25. PubMed ID: 27662632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Gene Polymorphisms/Haplotypes and Plasma Level of TGF-β1 in Susceptibility to In-Stent Restenosis Following Coronary Implantation of Bare Metal Stent in Chinese Han Patients.
    Chen HJ; Mo N; Zhang YF; Su GZ; Wu HD; Pei F
    Int Heart J; 2018 Jan; 59(1):161-169. PubMed ID: 29332922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.